Table 1.
Demographics and baseline characteristics of patients
| Eribulin (N = 30) | Nab-paclitaxel (N = 21) | Total (N = 51) | P value | ||
|---|---|---|---|---|---|
| Median age | (range) | 58 (31–76) yo | 58 (32–77) yo | 58 (31–77) | 0.5524 |
| Performance status | 0 | 10 (33%) | 20 (95%) | 30 (59%) | < 0.0001 |
| 1 | 18 (60%) | 1 (5%) | 19 (37%) | ||
| 2 | 2 (7%) | 0 | 2 (4%) | ||
| HER2 immunohistochemical staining | 3+ | 25 (83%) | 15 (71%) | 40 (78%) | 0.327 |
| 2+ (with FISH amplification) | 5 (17%) | 6 (19%) | 11 (22%) | ||
| Estrogen receptor | positive | 14 (47%) | 9 (43%) | 23 (45%) | 1.000 |
| negative | 16 (53%) | 12 (57%) | 28 (55%) | ||
| Progesterone receptor | positive | 5 (17%) | 6 (19%) | 11 (22%) | 0.327 |
| negative | 25 (83%) | 15 (71%) | 40 (78%) | ||
| Metastatic sites | visceral | 15 (50%) | 4 (19%) | 19 (37%) | 0.0389 |
| non-visceral | 15 (50%) | 17 (81%) | 32 (63%) | ||
| Previous chemotherapy regimens, median | (range) | 3.5 (1–9) | 1 (1–10) | 3 (1–10) | 0.0579 |